Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.

Trial Details

NCT ID
NCT03915678
Phase
PHASE2
Sponsor
Institut Bergonié
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Association atezolizumab + BDB001 + RT
  • Association atezolizumab + BDB001+ RT
Locations (sample)
  • Bordeaux, France|44.84124,-0.58046
  • Brest, France|48.39029,-4.48628
  • Caen, France|49.18585,-0.35912
  • Dijon, France|47.31344,5.01391
  • Lille, France|50.63391,3.05512

Key Eligibility Criteria

  • histologically confirmed pancreatic cancer, virus-associated tumors \[including papillomaviruses-related cancers (cervical, head and neck, and nasa…
  • Metastatic disease,
  • Age ≥ 18 years,
  • At least two lesions: one extra cerebral lesion that can be treated by radiotherapy and one site of disease that must be uni-dimensionally ≥ 10 mm …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →